ICER: In existence from more than 10 years, Institute for Clinical and Economic Review rose to prominence in 2014 with its evaluation of Gilead's Sovaldi (sofosbuvir) and other hepatitis C drugs. Since then it has finalized 15 reports on drugs, most covering multiple treatments. ICER has five reports in progress for 2018, including for Spark's gene therapy Luxturna (voretigene neparvovec) and CAR-T agents, and has announced four other potential topics for this year.
ACC/AHA: American College of Cardiology and American Heart Association announced in 2014 they would begin to include a cost/value consideration in clinical practice guidelines and outlined a methodology for doing so.
ASCO: Originally unveiled in 2015, American Society for Clinical Oncology's value framework for oncology drugs has been through two iterations and society continues to fine tune. ASCO also developing an online drug valuation tool for office-based discussions between physicians and patients.
NCCN: Released in 2015, National Comprehensive Cancer Network's "evidence blocks" meant to illustrate cancer drug attributes, including affordability, to be included in clinical practice guidelines.
Avalere/FasterCures: Patient-perspective value framework: Version 1.0 released in May 2017. Framework considers factors such as functional and cognitive status, symptom relief, complexity of regimen, and medical as well as non-medical out-of-pocket costs to the patient and family, and weights them in accordance with assessed patient preferences.
Memorial Sloan Kettering Cancer Center: DrugAbacus is a web-based tool to calculate value-based prices for cancer drugs. Unveiled in 2015, tool is designed to drive drug pricing policy discussions.
Innovation Value Initiative: Supported by funding from health consultancy Precision Health Economics and pharmaceutical firms, Open-Source Value Project is described as a transparent, open source model developed through a consensus-driven process. First application of the model is to drugs for rheumatoid arthritis and the next will focus on oncology. IVI plans to release one to two distinct models each year.

Valuing Drugs In The US: How We're Doing And What's Ahead

More from Health Technology Assessment

More from Market Access